TOP GLOVE

CORPORATION BHD

Corporate Presentation

July 2018

Bursa Malaysia : 7113 SGX : BVA Reuters : TPGC.KL Bloomberg : TOPG MK ADR CUSIP : 890534100

Top Glove business

ethics

Ready, 1 2 3

Claps, 2x 3x2x

Prepared By: Ng Chin Yong @14/07/17

Checked & Verified By: Ng Yong Lin @14/07/17

2

Disclaim

er

3

This document and any related presentations have been prepared by Top Glove Corporation Bhd (the “Company”). This document and any related presentations are being given

solely for your information and for your use and may not be taken away, reproduced or redistributed to any other person. By attending this presentation, you are agreeing to be

bound by these restrictions. Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The information contained in this document (the “Information”) is strictly confidential and has been provided by the Company and has not been independently verified. No

representation or warranty express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or

opinions contained herein. It is not the intention to provide, and you may not rely on this document as providing, a complete or comprehensive analysis of the Company’s business,

financial condition, results of operations, trading position or prospects. The Information and opinions in this document are provided as at the date of this document and are subject

to change without notice. Neither the Company nor any of its affiliates, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss

howsoever arising from any use of this document or its contents or otherwise arising in connection with this document.

Certain data in this document was obtained from various external data sources, and the Company has not verified such data with independent sources. Accordingly, the Company

makes no representations as to the accuracy or completeness of that data, and such data involves risks and uncertainties and is subject to change based on various factors.This document contains, and any related presentations may contain, financial information regarding the businesses and assets of the Company and its consolidated subsidiaries.

Such financial information may not have been audited, reviewed or verified by any independent accounting firm. The inclusion of such financial information in this document or any

related presentation should not be regarded as a representation or warranty by the Company, any of its affiliates, advisors or representatives or any other person as to the

accuracy or completeness of such information’s portrayal of the business, financial condition, results of operations, trading position or prospects by the Company and should not be

relied upon when making an investmentdecision.

This document includes forward-looking statements prepared by the Company. The opinions, forecasts, projections and other statements (except statements of historical fact),

including, without limitation, financial results for 1HFY2018, are forward-looking statements. Although the Company believes that the expectations reflected in such forward-

looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. All forward-looking statements contained in this document are

expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Each forward-looking statement speaks only as of the date of this

document. Neither the Company nor any of its affiliates, advisors or representatives undertakes any obligation to publicly update or revise any forward-looking statement as a

result of new information, future events or other information. In light of these risks, actual results could differ materially from those stated, implied or inferred from the forward-

looking statements contained in thisdocument.This document and any related presentation does not constitute or form part of an offer, solicitation or invitation of any offer, to subscribe for or purchase any securities and

nothing contained herein shall form the basis of, or be relied on, in connection with any contract or commitment whatsoever. Any decision to purchase securities in the context of a

proposed offering undertaken in the future by the Company, if any, should be made on the basis of information contained in the offering document published in relation to such an

offering. Any securities offered by the Company or any of its subsidiaries will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and may

not be offered or sold in the United States absent registration under the Securities Act or an applicable exemption to registration.

Any securities offered by the Company or any of its subsidiaries will be offered to (1) persons in Labuan or outside Malaysia or entities established or registered under the laws of

Labuan and (2) persons falling within the categories of excluded offers and invitations of debentures as set out in Section 8(5) of the Labuan Financial Services and Securities Act

2010 ("LFSSA"). This document, any related presentation or any copy thereof may not be taken or transmitted or distributed, directly or indirectly, into the United States, Canada,

Australia or Japan. The Company does not intend to register any offering of securities in the United States or conduct any public offering of securities in the United States.The distribution of this document and any related presentation in other jurisdictions may be restricted by law and persons into whose possession this document or any relatedpresentation comes should inform themselves about, and observe, any such restriction. Any failure to comply with these restrictions may constitute a violation of the laws of anysuch other jurisdiction.

Top Glove Corporation Bhd (“Top Glove”)

at a glance

57.5 billion gloves pa

39 factories

618 production

lines(1)

2,000+ customers

across 195

countries

FY17 Revenue of

RM3.4bn (USD 882mn)

and PATMI of RM0.3bn

(USD85mn)(3)

Current market

capitalisation(2) of

RM15.4bn

(USD 3.81bn)

Global leader in

medical and

surgical gloves

Source: Bloomberg

Notes:

(1) Include Aspion Sdn Bhd (“Aspion”)

(2) Market capitalisation as at 02 July 2018. Translated at FX rate of USD1:RM4.040 for convenience

(3) Based on Top Glove’s consolidated financial results for FYE 31 Aug 2017. Excludes Aspion (RM0.6bn (USD162mn) revenues for FYE 31 Oct 2016). PATMI refers to profit after tax and minority interests. Translated at FX rate of

USD1:RM3.8643 for convenience

World’s largest manufacturer of

gloves

Aspion:

a transformational

acquisition

Over 17,000

employees(1)

4

From humble origins to global

leaderNearly 3 decades of track record of

excellence

Note:

(1) Translated at FX rate of USD1:RM3.8643 for convenience

1991

▪ Started asa local business enterprise

2013▪ Established first

dedicated GroupR&D Centre to drive innovation

▪ Acquisition of the remaining minority stake in Medi-Flex and privatisation of the company

1994

▪ First overseas foray

and established a

marketing arm inthe

USA

2006

▪ Acquisition of amajority

stake in Medi-Flex

2007

▪ Revenues over RM1bn

2016

▪ Secondary listing on

Singapore StockExchange (“SGX”)

2017▪ Investment in new

business line- condom projected to beoperational by mid-2018

▪ Revenues overRM3bn

(USD776mn)(1)

2018

▪ Acquisition of Aspion

▪ Acquisition of EasternPress

▪ Proposed acquisition of

Duramedical

2010

▪ Revenues over RM2bn

2011▪ Acquired a marketingarm

in Germany to extend sales in Europe

2002

▪ Commenced operations in

China

▪ Established a second rubber

glovefactory in Thailand

▪ Transferred to the Main Board

of KLSE

2001

▪ Commenced operations inThailand

▪ Listed on the Second Board of Kuala Lumpur StockExchange (“KLSE”)

5

Tan Sri Dr Lim Wee Chai

Lim Hooi SinPuan Sri Tong Siew Bee

▪ Founded Top Glove in 1991

▪ Over 30 years of experience in rubber glove industry in Malaysia

▪ Served as the President of the Malaysian RubberGlove Manufacturers’ Association (“MARGMA”)

▪ Present appointments include President of the Federation of Malaysian Manufacturers, Director and Board Member of Employees ProvidentFund, Honorary President of the Malaysia-China Chamber of Commerce

Founder

Executive Chairman

Length of service: 27 years

Relevant experience

Dato Lee Kim Meow

▪ Joined Top Glove in1997 Appointed Managing Director in 2003

▪ Present appointments include Chairman of the ASEAN Rubber Glove ManufacturersAssociation (“ARGMA”) and Trustee of MARGMA Foundation

Managing Director

Length of service: 21 years

Relevant experience

Relevant experience

Executive Director

Length of service:27 years

▪ Joined Top Glove in 1991 Appointed Executive Director in 2000

▪ Responsible for thecomputer and information systems, human resource and general administration

▪ Over 30 years of experience in the rubber glove and banking industries

Relevant experience

▪ Founded TG Medical USA Inc, a wholly-owned subsidiary of Top Glove in 1994. Appointed Executive Director in 2000

▪ Responsible for product development,marketing, sales

▪ Over 30 years of experience in the rubber glove industry in USA and Malaysia

Executive Director

Length of service:24 years

Lim Cheong Guan

Relevant experience

▪ Joined Top Glove in2005 Appointed Executive Director in 2006

▪ Responsible for the accounting, treasury, corporate finance and investor relations

▪ Over 28 years of experience in the field of audit, manufacturing, plantation, trading and property development

Executive Director CFO

Length of service: 13 years

Low Chin Guan

Relevant experience

▪ Appointed Executive Director in 2018 pursuantto the acquisition of Aspion

▪ Over 30 years of experience in the rubber glove industry in Malaysia

▪ Prior to Top Glove, founded the initial subsidiary of Adventa Berhad (Aspion) in 1988

Executive Director

Founder of Aspion

Led by an experienced senior

management team

6

4 310 12 14

2127

32

66 68

99 99 99

143

182 182

0

20

40

60

80

100

120

140

160

180

200

0.0

2.0

4.0

6.0

8.0

10.0

Mar-01 Mar-02 Mar-03 Mar-04 Mar-05 Mar-06 Mar-07 Mar-10 Mar-11 Mar-12 Mar-13 Mar-14 Mar-15 Mar-16 Mar-17 Mar-18Mar-08 Mar-09

Annual Dividends TopGlove

02 July 2018:

RM 12.06

27 March 2001:

RM 0.13(1)

(IPO price adjustedfor

bonus issue andshare

split since IPO)

Share

Pri

ce

(RM

)

Total Shareholder Return:

9,718%

99

Number of shares held(1) Market value Accumulated

dividends

Investment cost

(as at 27 March 2001)

Capital

appreciation(2)

Total shareholder

return(as at 02 July 2018)

# RM RM RM RM %

20,384 245,831 19,264 (2,700) 262,395 9,718%

With initial investment of 1,000 shares made based on IPO price of RM2.70 on 27 March 2001,

the return would be:

Div

idends

(RM

mn)

Source: Bloomberg as of 02 July 2018

Notes:

(1) 1,000 shares at IPO, adjusted for bonus issue and share split since IPO

(2) Calculated based on adding market value and accumulated dividends and subtracting the investment cost

Track Record of Delivering Shareholder Value

Total dividend payment of RM1.16 billion since listing in

year 2001

12.0

103

127135

173

220

2005 2008 2011 2014 2018E

Steady growth in global demand for rubber gloves

Developed countries

(USA, EU29 and Japan)

% of World

Population

% of GlobalGlove

Consumption

70% 30%18% Other regions 82%

CAGR 05-18:

6.0%

Driven by strong market fundamentals across geographies

▪ As a protective barrier for medical staff, gloves are an indispensable

item in the healthcare sector, with increasing customer awareness in

developing markets

▪ Increasing hygiene standards and healthcare awareness

▪ Non-medical sector in developed countries

▪ Medical sector in developing countries

▪ A growing ageing population

▪ With the elderly being more susceptible to higher risk diseases

▪ Progressively stringent health regulations

▪ Healthcare reforms in US, China

▪ Healthcare regulations: OSHA in the US, EU-OSHA in Europe, SESI

in Brazil

▪ Emergence of new health threats

▪ A(H1N1), SARS, bird flu, ebola, bio-terrorism,Anthrax

Strong industry

fundamentals

Further growth potential from emerging markets

Based on 2016 statistics

% of World

Population

% of GlobalGlove

Consumption

In billion pieces

8

Source: Malaysia Rubber Gloves Manufacturer Association, International Trade Centre and Company & www.worldmeters.info

✓

Aspion Acquisition

(General Surgery)

(Disposable)(Examination)

(Examination) (Thermoplastic) (Cast Polyethylene)

(Disposable,

Household)

Latex Powdered

Nitrile

Specialised

Surgical

CPE/ TPE

Vinyl

(Examination) (Disposable, (Disposable)

Household)

(Disposable)

✓

✓ ✓(Disposable)

✓(Examination)

✓ ✓✓

✓ ✓ ✓

1

1

Latex Powder-free

(Examination)

✓ ✓(Disposable, (Disposable)Household)

✓

Sale

Contribution

Product

Category

1H18 Sales Volume (including Aspion)

Surgical Industrial Food

Majority of revenues

(Specialised

Surgery)

✓ ✓ ✓

✓(General Surgery)

✓(General Surgery)

1

Top 3

Key Markets Medical

▪ Mainly developed

markets (Europe)

▪ Global

▪ Global

▪ Mainly developing

markets

▪ Mainly developed

markets (USA,

Europe, Japan)

▪ Global

24%

19%

38%

12%

5%

2%

Market leader with extensive range of productsExtensive products mix applied in diverse industries, with a strong focus on

medical / surgical sector

Applications / industry Market Position

9

Continuous growth in manufacturing

capabilitiesChina

▪ 1 Glove Factory

Producing:

▪ Vinyl gloves

Malaysia

▪ Headquarters

▪ 28 Glove Factories

▪ 2 Chemical Factories

▪ 1 Glove Former

▪ 1 Packaging factory

▪ 1 Dental Dam factory

▪ 1 Condom Factory

Producing:

▪ Latex & nitrile examination

gloves

▪ Surgical, household,

cleanroom, CPE/TPEgloves

▪ Former & Chemical

Manufacturing

▪ Dental Dam

▪ Condom

Thailand

▪ 2 Latex Plants

▪ 2 Glove Factories

Producing:

▪ Latex examination gloves

▪ Latex concentrate

Clear blueprint for further growth

▪ Boosting nitrile capacity in tandem with growingdemand

▪ Faster, more efficient and technologically advanced production lines

▪ Increased automation throughout the manufacturing process

▪ On-going facility optimisation initiatives which include the construction of highly-efficient factories

10

Manufacturing Glove typeNumber of

production

lines

Capacity (pieces per

annum)

Current:

Top Glove: 28 glove factories All 543 lines 52.7 bn

Aspion: 3 glove factoriesSurgical,

Nitrile,

Latex

75 lines 4.8 bn

Total 31 glove factories 618 lines 57.5 bn

Expansion in progress :

Glove

F31 New factory (July 2018) Nitrile 30 lines 3.0 bn

F32 New factory (early 2019) Nitrile 44 lines 4.4 bn

Total expansion 74 lines 7.4 bn

Total by early 2019: 33 glovefactories 692 lines 64.9 bn

Expansion in progress:

Condom

F35CD New factory (June

2018)

Latex 2 lines 0.2 bn

Latex Processing

Top Glove: 2 latex plants Sourcing majority of the latex requirements

Global distribution across 195

countries

GermanyUSA China

Malaysia

Thailand

Geography 3-year average

sales volume

growth rate

North America 10.8%

Europe 11.3%

Japan 13.2%

Asia ex Japan 12.9%

Middle East 6.3%

Latin America 3.8%

Africa (8.1%)

Global 8.8%Legend:

Distribution hub

Distribution

▪ Over 2,000 customers

▪ Comprising distributors across

195 countries

▪ A geographically diverse

customer base

▪ An OEM manufacturer inevery

region

▪ Top 20 customersrepresent

c.25% of total revenue

▪ No single customer contributes

more than 4% of revenue

Europe

30%

North America

25%

Latin America

11%

Asia ex-Japan 15%

Middle-East 8%

Japan 8%

3%

9M18 Sales VolumeBreakdown

(including Aspion)

Africa

Brazil

11

442

525484

395289

17.6% 18.2%

14.2% 11.5%13.2%

280361 329

234335

12.5%

9.6% 9.4%11.2%

334

434381

178

299

Proven track record of growth and

profitability

Revenue and growth EBITDA and margins(2)

Cash flow from operationsPATMI and margins(3)

RMmn (x)

12

With strong operating

cashflows

CAGR of 4.7%

Growth = 36.7%

2015

USD114mn

2016

USD136mn

2017

USD125mn

9M17

USD75mn

9M18

USD102mn

RMmn

11.1%

USD Equivalent(1)

2015

USD72mn

2016

USD93mn

2017

USD85mn

9M17

USD61mn

9M18

USD87mn

CAGR of 6.8%

Growth = 68.0%

2015

USD86mn

2016

USD112mn

2017

USD99mn

9M17

USD17mn

9M18

USD40mn

RMmn

YoY volume growth 8% 11% 7% 25%

CAGR of 16.5%

3,409 Growth =

2,5112,889 19.6%

2,9972,507

USD Equivalent(1)

2015USD650mn

2016USD747mn

2017USD882mn

9M17 9M18

USD649mn USD776mn

Notes:

Financials based on Top Glove consolidated financials for the relevant period without adjusting for the impact of the acquisition of Aspion

(1) Translated at FX rate of USD1:RM3.8643 for convenience

(2) EBITDA refers to earnings before interest, tax, depreciation and amortisation. EBITDA margins refer to EBITDA over Revenue

(3) PATMI refers to profit after tax and minority interests. Net profit margins refer to PATMI over Revenue

CAGR of 8.4%Growth =

43.2%

Prudent capital

management

Adjusted net debt / (adjusted net cash) position Gearing ratio (D/E)

Cash flow from operations / debtAdjusted net debt / EBITDA

RMmn (x)

(x) (x)

(0.41x)

(0.58x)

(0.15x)

2015 2016 2017

0.53x

1.09x1.01x

2015 2016 2017

Adjusted net debt /

(Adjusted netcash)(1) 0.40x

0.22x0.19x

0.18x

0.91x

31 Aug 15 31 Aug 16 31 Aug 17 31 May 17 31 May 18

146

636399 376 345

224 240 213 191

2069

670 479207 227 248

31 Aug 15 31 Aug 16

Cash Debt

31 Aug 17 31 May 17 31 May 18

Short-term investment securities

13

(180) (304) (71) (95) 1630

Note: Financials based on Top Glove consolidated financials for the relevant period without adjusting for the impact of the acquisition of Aspion

(1) Adjusted net debt / (adjusted net cash) is calculated by subtracting cash and short-term investment securities from total debt

Healthy balance

sheet

14

Notes:

(1) Adjusted for certain events after 31 August 2017 comprising of:

a. the exercise of 2,145,060 ESOS Options between 1 September 2017 and 04 April2018; and

b. the acquisition by the Company of the entire equity interest in Aspion, completed on 4 April 2018. The purchase consideration was satisfied by:

(i) RM1,233.0 million in cash, which was funded via conventional term loan and Islamic term financing; and

(ii) the issuance of 20,505,000 new Top Glove Shares at RM6.6813

(2) Translated at FX rate of USD1:RM3.8643 for convenience

(3) Adjusted net debt / (adjusted net cash) is calculated by subtracting cash and short-term investment securities from total debt

In RMmn As of 31 Aug 2017Proforma

post Aspion acquisition(1)

RMmn USDmn(2)

RMmn USDmn(2)

Cash and bank balances 240.1 62.1 258.4 66.9

Borrowings 376.4 97.4 1,890.0 489.1

Net debt / (net cash) 136.3 35.3 1,631.6 422.2

Shareholders’ equity 2,003.3 518.4 2,142.0 554.3

Debt / equity (x) 0.19x 0.88x

Net debt / equity (x) 0.07x 0.76x

Investment in securities 206.9 53.5 206.9 53.5

Adjusted cash 447.0 115.7 465.3 120.4

Adjusted net debt / (adjusted net cash)(3)

(70.6) (18.3) 1,424.7 368.7

Adjusted net debt / equity (x)NM (adjusted

net cash)0.67x

Aspion – A highly synergistic and transformational

acquisitionHighly synergistic

acquisition

Top Glove becomes world #1 manufacturer(1) in surgical and medical gloves globally,withleading low-cost and high-techcapabilities

Access to new customers, specifically in developed markets of US, Europe andJapan

Overcome high barriers entry in the surgical gloves market, including regulatory approvals

Financially attractive acquisition

3

4

1

2

Access to cutting edge technology and premium product offering that isexpected to lead

the trend in preference glove adoption in developed nations

5

15

Source: Company, Frost and Sullivan Global Surgical Gloves Market (July 2017)

Note:

(1) Based on production volume

17%

21%

17%

13%

12% (1)

10%

1%

Becoming the #1 surgical glove manufacturer in

the world(1)

Others 26%

Propels Top Glove to become the #1 surgical glove manufacturer(1)… … accessing new clients in key developed markets in surgical gloves

12% 29% 1

▪ Immediate access and opportunity to tap developed and new

markets including the US with high surgical glove consumption/

capita

▪ Complementary fit with Top Glove’s existing surgical glove markets

due to minimal duplication

▪ Diversify the risk profile of Top Glove surgical glovebusiness

segment by expanding into developed countries

16

Geographical breakdown of surgical gloves annual sales(2) (volume)

Aspion Top Glove

North America 7.3% -

Western Europe 22.1% 1.0%

Japan 5.0% -

Middle East 23.1% 13.0%

South America 18.8% 15.0%

Asia 20.0% 26.0%

Eastern Europe 2.5% 37.0%

Others 1.2% 8.0%

▪ Current surgical glove market is mainly dominated by multi-national corporations

▪ Post-acquisition, Top Glove will be the largest surgical glove producer globally

▪ Potential for capturing more production from MNCs in the future, hence increasing profitability

▪ Accelerates Top Glove’s plan to attain c.30% market share in the global rubber glove market by 2020

Competitor A

Competitor B

Competitor D

Competitor C

Source: Company, Frost and Sullivan Global Surgical Gloves Market (July 2017)

Note:

(1) Based on production volume. Top Glove market share based on Company’s estimates

(2) Top Glove figures based on financial year ending 31 August 2017 / Aspion figures based on financial year ending 31 October 2016

Access to new manufacturing knowledge and

proprietary materials

Acquisition of Aspion will complement existing Top Glove product range with cutting edge technology surgicalglove

Examination

gloves

Entry

Mid-range

Preference

Protection

▪ Orthopaedic

▪ Trauma

▪ High risk surgery

Comfort

▪ Microsurgery

▪ Neurosurgery

▪ Photorefractive keratectomy

Zero Chemicals

▪ General surgery

▪ Endoscopic surgery

▪ Obstetrics

▪ Gynaecology

Safety and No Allergens

▪ No latex allergens

▪ Zero chemical accelerators

▪ No chemical allergens

Protection (AQL(1)<0.1)

▪ Strong barrier efficiency

▪ Block passage of viruses

▪ Virtually nopinholes

Lasting Comfort

▪ Ultra low stress onhands

▪ Comfortable wear through surgery

Finessis’ flagship

surgical glove

consists of 3

brands

FUSIONFUSION

barrierONE

Sensiflex

Plus

Maxitex

NeuroPF

Maxitex

PF

Maxitex

UGPF

Maxitex

DuplexPFMaxitex

Maxitex

Duplex

Nuzone

X2

Ulma Fortis PF Ulma Fortis

Nugard NugardNitril Sensiflex

Cutting Edge Technology: FINESSISTM Surgical Glove Using FlexylonTM

5 years to develop Finessis using “Flexylon” material created using

proprietary R&D and approved by FDA, EU andTGA

Superior

Quality

Access to

cutting edge

technology

Top Glove will benefit from Aspion's premium product offering, enhanced by Aspion’s highly specialised Finessis product

that is expected to lead the trend in preference surgical glove adoption in developed markets

Note:

(1) AQL refers to Acceptable Quality Level

17

Profit guarantee:▪ Guarantee by the Vendor to reimburse the core PAT shortfall in

FY2018 and FY2019:

▪ If actual core PAT for FY2018 is less than RM80.9mn, the difference will be:

i. offset by the Finessis PAT for FY2018; andii. any remaining shortfall will be paid by Vendor to Top

Glove

▪ If actual core PAT for FY2019 is less than RM108.3mn, the shortfall will be paid by Vendor to Top Glove

▪ Aggregate amount to be paid by the Vendor in relation to the profit guarantee will not exceed RM100mn

Aspion transaction

highlights

Notes:

(1) FY refers to FYE 31 October

Salient terms of the transaction

1

2Finessis Incentive:

▪ Finessis is a new cutting edge technology product from AspionGroup with strong potential but currently unproven. PAT of theFinessis product includes sales of Finessis Gloves by the AspionGroup and fees, royalties and income received for the use of anyrights relating to Finessis gloves (“Finessis PAT”)

▪ Finessis PAT achieved was approx. RM1.0 million for FYE 31October 2017, the first financial year during which the FinessisGloves were commercialized

▪ Structure of Finessis Incentive allows the Group to reduce theinitial purchase consideration for a highly attractive new productwith strong potential but no proven sales track record yet and alignthe purchase consideration for Finessis with its future actualperformance

Purchase consideration arrived at after taking into account

risk of the acquisition

Acquisition ▪ 100% of Aspion Sdn Bhd (“Aspion”)

Vendor ▪ Adventa Capital Pte. Ltd. (“Vendor”)

Purchase price

▪ Total consideration: RM1,370 million, consisting of:

▪ RM1,233 million in cash

▪ 20.505 million of new Top Glove ordinary shares issued at a price at RM6.6813/share

Finessis Incentive

▪ Under the Finessis incentive, the Vendor will be entitledto the following payments:

Finessis % subject toPAT

PAT Finessis Finessis IncentiveAmount

period(1)

incentivemultiple

FY2018 20.0% 16.93 Finessis PAT x 20.0% x16.93

FY2019 30.0% 16.93 Finessis PAT x 30.0% x16.93

FY2020 50.0% 16.93 Finessis PAT x 50.0% x16.93

Profit guarantee▪ Guarantee by the Vendor to reimburse any core PAT

shortfall in FY2018 and FY2019 up to RM100mn

Completion ▪ 04 April 2018

18

Conclusi

on

Market leader

▪ World’s largest manufacturerof gloves

▪ Market leadership in all key product segments

Attractive industry

fundamentals

▪ Strong growth in usage of rubber gloves historically in developed countries

▪ Future growth potential from emerging markets

Positioned strongly

for growth

▪ Continuous growth in manufacturingcapacities

▪ Global distribution network across 195 countries

Strong financial

performance

▪ Strong historical growth in revenue andearnings

▪ EBITDA margin of 15-16% and strong operatingcash flows generation

▪ Prudent capital management with strong balance sheet

Aspion acquisition

▪ Highly synergistic and accretive acquisition

▪ Propels Top Glove to the #1 surgical glove manufacturer globally

4

5

3

2

1

19

Thank

You

20

Appendix

21

Top Glove guiding

principles

Vision:We strive to be the world’s leading manufacturer with

excellent quality glove products and services that enrich and protect humanlives

Corporate To be a world class glove manufacturer by providingMission: top quality products with excellent services through continuous improvement and innovation

Business Direction Business Philosophies

▪ To produce consistently high quality gloves at efficient low cost ▪ We work for ourcustomers

▪ We take care of the interest of our shareholders

▪ We ensure that our employees continue to contribute positively to the

company and we care fortheir well-being

▪ We work closely with our bankers, suppliers, business associates

and friends

Business Rules

▪ Do not lose our shareholders’money

▪ Do not lose our health

▪ Do not lose our temper

▪ Do not lose our customers

Investment Direction

▪ To invest 1 efficient dollar and earn 2 healthy dollars

Business Ethics

▪ Honesty

▪ Integrity

▪ Transparency

22

Top Glove strong CSR

stewardship

▪ All factories in the

process of being

ISO 14001 certified

▪ On-site Detention

tanks and rain

harvesting tanks

installed in factories

▪ All Klang factoriesare

strategically located

within 500m of each

other, minimising fuel

consumption

▪ Rubber waste sentto

government certified

companies for

purposes of recycling

Transportation

Water Efficiency

Waste Management Practices

Environment

ISO 14001

▪ Launched with the objective ofproviding

funds for the purpose of charity,

education, environment andcommunity

Social

Top Glove Foundation

Community Outreach Program

▪ Well-being of our employees continues

to be a foremostpriority

▪ Policies to govern our hiringprocesses

and protect our workforce

Employees

Learning & Development

▪ A learning organisation with themotto:

“Must Know, Must Do, Must Teach”

Talent Recruitment & Attraction

▪ Stringent policies to hire well-rounded

talents and provide opportunities for

future leaders

Corporate Wellness

▪ Committed to serve thecommunity

Fair & Equitable Work Environment

23

Top Glove group of

companies

Prepared by : QA Admin (Rev. 6, Date Prepared : 14/7/17)

Verified by : Ms. Loo Sun Nooi / QA DGM

Ready, 1 2 3

TOP GLOVE

Top Quality

Top Quality

Top Quality

Claps, 2X 3X 2X

YES! YES! YES!

24